173 related articles for article (PubMed ID: 24349459)
1. Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.
Kusano H; Akiba J; Ogasawara S; Sanada S; Yasumoto M; Nakayama M; Ueda K; Ueda K; Kurita T; Todoroki K; Umeno Y; Nakashima O; Yano H
PLoS One; 2013; 8(12):e83195. PubMed ID: 24349459
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.
Yano H; Ogasawara S; Momosaki S; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Kuratomi K; Basaki Y; Oie S; Kuwano M; Kojiro M
Liver Int; 2006 Oct; 26(8):964-75. PubMed ID: 16953837
[TBL] [Abstract][Full Text] [Related]
3. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Kusano H; Ogasawara S; Akiba J; Nakayama M; Ueda K; Yano H
Int J Oncol; 2013 Jun; 42(6):1897-903. PubMed ID: 23588838
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.
Thompson MD; Dar MJ; Monga SP
J Hepatol; 2011 Mar; 54(3):506-12. PubMed ID: 21093092
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155.
Zhang Y; Li X; Zhang Y; Wang L; Xu J; Du J; Guan Y
Ann Hepatol; 2019; 18(3):494-500. PubMed ID: 31036495
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo.
Hisaka T; Yano H; Ogasawara S; Momosaki S; Nishida N; Takemoto Y; Kojiro S; Katafuchi Y; Kojiro M
J Hepatol; 2004 Nov; 41(5):782-9. PubMed ID: 15519651
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.
Motawi TK; El-Boghdady NA; El-Sayed AM; Helmy HS
Tumour Biol; 2016 Feb; 37(2):1617-25. PubMed ID: 26304505
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
Moriya F; Ogasawara S; Basaki Y; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Nishida N; Matsuoka K; Kojiro M; Kuwano M; Yano H
Int J Oncol; 2008 Oct; 33(4):647-55. PubMed ID: 18813777
[TBL] [Abstract][Full Text] [Related]
11. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo.
Ogasawara S; Yano H; Momosaki S; Akiba J; Nishida N; Kojiro S; Moriya F; Ishizaki H; Kuratomi K; Kojiro M
J Interferon Cytokine Res; 2007 Jun; 27(6):507-16. PubMed ID: 17572015
[TBL] [Abstract][Full Text] [Related]
14. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy.
Xu K; Lee F; Gao SJ; Chung JE; Yano H; Kurisawa M
J Control Release; 2013 Mar; 166(3):203-10. PubMed ID: 23328125
[TBL] [Abstract][Full Text] [Related]
15. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
[TBL] [Abstract][Full Text] [Related]
16. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
17. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
Erickson AK; Seiwert S; Gale M
Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Cao B; Chen XP; Zhu P; Ding L; Guan J; Shi ZL
World J Gastroenterol; 2008 Nov; 14(44):6802-7. PubMed ID: 19058305
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
[TBL] [Abstract][Full Text] [Related]
20. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.
Espinosa M; Arenas MD; Aumente MD; Barril G; Buades JM; Aviles B; Carretero D; Alvarez-Lara MA; Carnicer F; Martin-Malo A; Aljama P
Clin Nephrol; 2007 Jun; 67(6):366-73. PubMed ID: 17598372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
